Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer.
Breast CancerJun 10, 2026 (epub)
Tsuguo Iwatani, Norikazu Masuda, Shigehira Saji et al.
✦ AI-curated · Sources linked
In 30 seconds
The JBCRG-M06/EMERALD trial evaluated the impact of eribulin versus taxane on quality of life (QoL) in patients with HER2-positive locally advanced or metastatic breast cancer. The study found that the median time to QoL deterioration was significantly longer in the eribulin group at 7.16 months compared to 4.57 months for the taxane group, with a hazard ratio of 0.80.
Key findings
- Median time to QoL deterioration was 7.16 months for eribulin versus 4.57 months for taxane.
- 62.7% of patients in the eribulin group maintained QoL at 6 months compared to 43.5% in the taxane group.
- GHS scores in the eribulin group remained stable, while the taxane group experienced deterioration between weeks 9 and 27.
Why it matters
This study highlights the potential of eribulin to preserve quality of life in patients undergoing treatment for HER2-positive breast cancer, which is crucial for patient well-being and treatment adherence.